Dong Xu

Dr. Dong Xu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2020 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
HSHaiying Sun
Haiying Sun
RNRuoqi Ning
Ruoqi Ning
YTYu Tao
Yu Tao
CYChong Yu
Chong Yu
XDXiaoyan Deng
Xiaoyan Deng
DXDong Xu
Dong Xu

28 October 2022 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
JCJia Chen
Jia Chen
MXMingYou Xing
MingYou Xing
DXDong Xu
Dong Xu
NXNaNa Xie
NaNa Xie
WZWenCong Zhang
WenCong Zhang
JSjianxin song
jianxin song
Background: This study aims to analyze the 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) characteristics of different causes of fever of unknown origin (FUO) and identify independent predictors to develop a suitable diagnostic model for distinguishing between these causes. A total of 524 patients with classical FUO who underwent standard diagnostic procedures and PET/CT were prospectively studied. The diagnostic performance of PET/CT imaging was analyzed, and relevant clinical parameters that could improve diagnostic efficacy were identified. The model was established using the data of 369 patients and the other 155 patients comprised the validation cohort for verifying the diagnostic performance of the model. Results: The metabolic characteristics of the “hottest” lesion, the spleen, bone marrow, and lymph nodes varied for various causes. PET/CT combined with clinical parameters achieved better discrimination in the differential diagnosis of FUO. The etiological diagnostic models included the following factors: multisite metabolic characteristics, blood cell counts, inflammatory indicators (erythrocyte sedimentation rate, C-reactive protein, serum ferritin, and lactate dehydrogenase), immunological indicators (interferon gamma release assay, antinuclear antibody, and anti-neutrophil cytoplasm antibody), specific signs (weight loss, rash, and splenomegaly), and age. In the testing cohort, the AUCs of the infection prediction model, the malignancy diagnostic model, and the noninfectious inflammatory disease prediction model were 0.89 (95% CI 0.86–0.92), 0.94 (95% CI 0.92–0.97), and 0.95 (95% CI 0.93–0.97), respectively. The corresponding AUCs for the validation cohort were 0.88 (95% CI 0.82–0.93), 0.93 (95% CI 0.89–0.98), and 0.95 (95% CI 0.92–0.99), respectively. Conclusions: 18F-FDG PET/CT has a certain level of sensitivity and accuracy in diagnosing FUO, which can be further improved by combining it with clinical parameters. Diagnostic models based on PET/CT show excellent performance and can be used as reliable tools to discriminate the cause of FUO. Trial registration This study (a two-step method apparently improved the physicians’ level of diagnosis decision-making for adult patients with FUO) was registered on the website http://www.clinical-trials.gov on January 14, 2014, with registration number NCT02035670.

14 October 2020 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
XLXinjie Li
Xinjie Li
TMTuohutaerbieke Marmar
Tuohutaerbieke Marmar
QXQiang Xu
Qiang Xu
JTJing Tu
Jing Tu
YYYue Yin
Yue Yin
DXDong Xu
Dong Xu
To determine what exacerbate severity of the COVID-19 among patients without comorbidities and advanced age and investigate potential clinical indicators for early surveillance, we adopted a nested case−control study, design in which severe cases (case group, n = 67) and moderate cases (control group, n = 67) of patients diagnosed with COVID-19 without comorbidities, with ages ranging from 18 to 50 years who admitted to Wuhan Tongji Hospital were matched based on age, sex and BMI. Demographic and clinical characteristics, and risk factors associated with severe symptoms were analysed. Percutaneous oxygen saturation (SpO2), lymphocyte counts, C-reactive protein (CRP) and IL-10 were found closely associated with severe COVID-19. The adjusted multivariable logistic regression analyses revealed that the independent risk factors associated with severe COVID-19 were CRP (OR 2.037, 95% CI 1.078–3.847, P = 0.028), SpO2 (OR 1.639, 95% CI 0.943–2.850, P = 0.080) and lymphocyte (OR 1.530, 95% CI 0.850–2.723, P = 0.148), whereas the changes exhibited by indicators influenced incidence of disease severity. Males exhibited higher levels of indicators associated with inflammation, myocardial injury and kidney injury than the females. This study reveals that increased CRP levels and decreased SpO2 and lymphocyte counts could serve as potential indicators of severe COVID-19, independent of comorbidities, advanced age and sex. Males could at higher risk of developing severe symptoms of COVID-19 than females.

1 July 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
XLXinjie Li
Xinjie Li
YYYue Yin
Yue Yin
LPLing Pang
Ling Pang
SXShuyun Xu
Shuyun Xu
FLFeng-min Lu
Feng-min Lu
TSTao Shen
Tao Shen
A large number of COVID-19 patients are in recovery and millions of people are vaccinated COVID-19 vaccines globally daily. This calls for a rapid screening strategy of SARS-CoV-2 protective antibodies generated in rehabilitators and vaccinated populations. Serum samples collected over a follow-up period of 6 months from 306 COVID-19 cases discharged from Wuhan Tongji Hospital were analyzed. Anti-S Abs were detected by colloidal gold immunochromatographic assay (GICA) and neutralizing antibodies (nAbs) were detected by chemiluminescent microparticle immunoassay (CMIA). Most COVID-19 survivors tested positive for anti-S Abs (83.7%) and nAbs (98.0%) 6 months after being discharged from the hospital, and the levels of anti-S Abs in the blood were highly positively correlated with nAbs (r = 0.652, P < 0.0001). The positivity rate of nAbs for patients with anti-S Abs positive was 100%. There is a good agreement between anti-S Abs detected by GICA and nAbs detected by CMIA. It indicates that anti-S Abs detected by GICA may be used as a cheaper screening strategy for detectable SARS-CoV-2 nAbs in COVID-19 convalescent individuals.

1 January 2021 in International Journal of Medical Sciences
Verified
Journal Article
Open access
HCHuilong Chen
Huilong Chen
XLXinjie Li
Xinjie Li
TMTuohutaerbieke Marmar
Tuohutaerbieke Marmar
QXQiang Xu
Qiang Xu
JTJing Tu
Jing Tu
TSTao Shen
Tao Shen
Background: For coronavirus disease 2019 (COVID-19), early identification of patients with serious symptoms at risk of critical illness and death is important for personalized treatment and balancing medical resources.

22 February 2017 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
CZChun-Hui Zhu
Chun-Hui Zhu
MZMan-Zhi Zhao
Man-Zhi Zhao
GCGuang Chen
Guang Chen
JQJun-Ying Qi
Jun-Ying Qi
JSJian-Xin Song
Jian-Xin Song
DXDong Xu
Dong Xu